Immupharma PLC CNRS Confirms Lupuzor's (TM) Effectiveness
January 28 2013 - 4:33AM
RNS Non-Regulatory
TIDMIMM
Immupharma PLC
28 January 2013
FOR IMMEDIATE RELEASE 28 JANUARY 2013
RNS REACH
CNRS Confirms Lupuzor's (TM) Effectiveness
ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, is pleased to
announce that its key scientific collaboration partner and the
inventor of ImmuPharma's lead compound, Lupuzor(TM) has issued a
press release confirming the effectiveness of the Lupuzor(TM)
peptide P140.
Lupuzor(TM) is ImmuPharma's lead compound and potential
blockbuster drug for Lupus, a chronic autoimmune disease.
Lupuzor(TM) has received Special Protocol Assessment and Fast Track
Designation from the FDA for a Phase III trial.
CNRS Press Release : Summary
A clinical trial with 149 patients suffering from the very
disabling autoimmune disease systemic lupus erythematosus, has
shown the effectiveness of a synthetic peptide developed by a team
of researchers led by CNRS biologist Slyviane Muller (see notes to
Editors) at the Institut de Biologie Moleculaire (IBMC) in
Strasbourg, France. The peptide, known as P140/Lupuzor(TM) , is
well tolerated by patients and leads to regression of the disease.
Under the CNRS patent, ImmuPharma-France, which funded the trial,
has an exclusive license to use the peptide. Now the final phase of
clinical tests should soon confirm these results and contribute to
the development of a drug without the side effects of existing
treatments, which use cortico-steroids and immuno-suppressants.
These results are published online in the Annals of the Rheumatic
Diseases.
For more information please see the attached PDF of the English
translation of the press release or via the CNRS website:
http://www2.cnrs.fr/presse/communique/823.htm or
http://www2.cnrs.fr/presse/communique/970.htm
http://www.rns-pdf.londonstockexchange.com/rns/4761W_-2013-1-28.pdf
Ends
For further information please contact:
+ 44 (0) 20 7152
ImmuPharma plc 4080
Dimitri Dimitriou, Chief
Executive Officer
Dr Robert Zimmer, President
and Chief Scientific Officer
Richard Warr, Chairman
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721 413496
Panmure, Gordon & Co., NOMAD
& Broker +44 (0) 20 7459 3600
Fred Walsh
Hannah Woodley
Notes to Editors
ImmuPharma
ImmuPharma is focusing on developing novel medicines with high
sales potential in specialist markets with serious unmet need.
ImmuPharma has five drug candidates in development, two platform
technologies and approximately 70 patents. The Company's most
advanced drug candidate, Lupuzor(TM) a potential blockbuster drug
for Lupus, a chronic autoimmune disease has recently received the
approval from the US FDA to enter phase III with a Special Protocol
Assessment and "Fast Track" designation. The Company's second
potential blockbuster compound in cancer "IPP-204106" is completing
a new Phase I/ II clinical trial with the next generation of
"polyplexed Nucant". ImmuPharma was founded and is led by a
commercially focused Board and management team with extensive
experience. For more information on ImmuPharma please go to
www.immupharma.com.
Lupuzor(TM) - treatment for lupus
Lupus (or Systemic Lupus Erythematosus) is a chronic,
potentially life-threatening autoimmune disease. An estimated 1.4
million people are diagnosed in the 7 major world markets (the USA,
Japan, Germany, France, Spain, the UK and Italy). Lupus is an
inflammatory disease, which attacks multiple organs such as the
skin, joints, kidneys, blood cells, heart and lungs. There is
currently no cure. More information on Lupuzor(TM) can be found
under www.lupuzor.com.
CNRS (Centre National de la Recherche / National Center for
Scientific Research)
The CNRS is Europe's largest fundamental research institution.
The CNRS was founded in 1939 and is a government-funded research
organization, under the administrative authority of France's
Ministry of Research and has over 30,000 employees and an annual
budget of over EUR3 billion. The CNRS has received many prestigious
awards and has produced 17 Nobel laureates and 11 Fields Medal
award winners.
Dr Sylviane Muller, Research Director at CNRS & Co-founder
of ImmuPharma France
Sylviane Muller is Professor at the Institute for Advanced Study
of the University of Strasbourg (USIAS), holder of the chair of
immunology and therapeutic chemistry, Distinguished class Research
Director and head of the 'Immunologie et chimie thérapeutiques'
unit of the "Centre National de la Recherche Scientifique" (CNRS),
the largest fundamental research organization in Europe. She
obtained her PhD at the University of Strasbourg. For two years,
she was a post-doctoral fellow in Freiburg (Germany) at the
Max-Planck Institute for Immunobiology. Her field of expertise
covers autoimmunity, immuno-peptides and synthetic vaccines. She
has made 23 patented discoveries and is widely published (330
publications and reviews/chapters). She was also a founder of
Neosystem, now Polypeptide-France, a leading peptide development
and manufacturing company. She is the key inventor of ImmuPharma's
Lupus lead drug candidate Lupuzor and has been working in this
field for more than ten years.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGCGDBCDDBGXI
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024